Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Psoriasis 1Plaque, Amyloid 1Lymphoma, Follicular 1Bronchiolitis Obliterans Syndrome 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × sodium luminolate × Clear all
NCT02908347 2019-01-23

Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients

MetrioPharm AG

Phase 2 Completed
46 enrolled 24 charts
Lymphoid

Bronchiolitis Obliterans Syndrome, Lymphoma, Follicular, Psoriasis, Plaque, Amyloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡